A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)

NCT05296798 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

922

Enrollment

INDUSTRY

Sponsor class

Conditions

Locally Advanced or Metastatic Breast Cancer

Interventions

DRUG: Phesgo
DRUG: Giredestrant
DRUG: Docetaxel
DRUG: Paclitaxel
DRUG: LHRH Agonist
DRUG: Optional Endocrine Therapy of Investigator's Choice

Sponsor

Hoffmann-La Roche